Neurofeedback vs Medications: Efficiency and Long-term Effects

The treatment landscape for neurological and psychological conditions has evolved significantly in recent decades. While medication-based interventions have long dominated clinical practice, neurofeedback has emerged as a compelling, non-invasive alternative that aims to train the brain to regulate its activity. This article examines the comparative effectiveness of these approaches, with particular focus on their immediate outcomes and long-term sustainability.

Recent clinical studies have provided valuable insights into the relative effectiveness of neurofeedback and medication-based treatments during active intervention periods. The metrics used to evaluate success vary across studies but typically include cognitive performance, behavioural measures, and academic achievement.

The timeline of effectiveness represents a key distinction between these approaches. Medication typically produces rapid initial results, often within hours or days of administration. Studies report better response rates to stimulant medications in controlled trials, with improvements readily measurable through standardized attention tests and behavioural assessments. Neurofeedback, while requiring a longer initial investment, shows progressive improvements across multiple domains as training advances. Research tracking academic performance reports that students receiving neurofeedback training demonstrate improvement in sustained attention, enhancement in working memory capacity, and reduction in impulsive responses.

These improvements typically manifest after 20-30 sessions, with some individuals requiring additional training for optimal results.

The gradual improvement curve of neurofeedback stands in contrast to the immediate effects of medication but may reflect deeper neurological changes occurring through the training process.

Long-term Sustainability of Neurofeedback Treatment Benefits

The most significant difference between neurofeedback and medication emerges in their long-term outcomes. Follow-up studies reveal distinct patterns of sustainability that have important implications for treatment decisions. The effects of medication generally persist only while under active treatment, with the benefits diminishing rapidly upon stopping treatment (Lin et al., 2022; Van Doren et al., 2019). Long-term studies of stimulant medications show a return to baseline symptoms within days to weeks of discontinuation, potential development of tolerance requiring dose adjustments, and variable effectiveness over extended periods. This pattern reflects the underlying mechanism of medication—it temporarily modifies brain chemistry without fundamentally changing neural pathways. Once the chemical influence is removed, the brain typically returns to its previous state.

In contrast, neurofeedback demonstrates remarkable sustainability of improvements after training completion. Studies tracking participants for 2-10 years post-treatment reported maintenance of attention and behavioural improvements in 70-80% of cases, continued enhancement of self-regulation abilities and reduced need for ongoing intervention (Arns et al., 2020; Van Doren et al., 2019).

This sustainability stems from neurofeedback's fundamental mechanism: training the brain to self-regulate rather than relying on external chemical modulation. The learned skills become integrated into neural circuits, creating lasting changes in brain function that persist beyond the training period.

Advantages of Neurofeedback

Several key advantages distinguish neurofeedback from medication-based approaches in the treatment of various neurological and psychological conditions.

·      Absence of Side Effects

While medications often come with a range of side effects, neurofeedback rarely produces adverse effects beyond occasional temporary fatigue during training. Common medication side effects include sleep disturbances, appetite suppression, mood alterations, and cardiovascular changes. These side effects can significantly impact quality of life and often prompt treatment discontinuation. Neurofeedback's minimal side effect profile represents a substantial advantage, particularly for individuals sensitive to medication effects or those requiring long-term intervention.

·      Customization Potential

Neurofeedback protocols can be precisely tailored to individual brain patterns and specific symptoms, offering a level of personalization that standardized medication dosing cannot match. Advanced neurofeedback approaches use quantitative EEG (QEEG) assessments to identify specific brainwave patterns associated with an individual's symptoms, allowing for targeted training of these neural signatures. This customization extends to adjusting protocols throughout the training process based on progress and response. As certain brainwave patterns normalize, practitioners can shift focus to address other aspects of neural dysregulation, creating a dynamic treatment process that evolves with the individual's needs.

·      Comprehensive Impact

Beyond target symptoms, neurofeedback often yields broader improvements in emotional regulation, sleep quality, cognitive flexibility, academic performance, and social interaction. This wide-ranging impact likely reflects neurofeedback's influence on fundamental neural regulatory mechanisms that underlie multiple domains of functioning. By improving the brain's overall self-regulation capacity, neurofeedback can address various interconnected symptoms simultaneously.

·      Efficacy in Medication-Resistant Cases

Neurofeedback has shown promise in cases where medications prove ineffective or poorly tolerated. Studies of medication-resistant epilepsy patients report 40-60% reduction in seizure frequency following neurofeedback training, while similar benefits have been observed in treatment-resistant depression and anxiety (Sudnawa et al., 2018). This effectiveness in medication-resistant cases suggests neurofeedback may work through neural mechanisms distinct from those targeted by conventional pharmacological approaches. By directly addressing neural dysregulation patterns, neurofeedback may bypass limitations associated with neurotransmitter-focused interventions.

Summary: Several key advantages distinguish neurofeedback from medication-based approaches in the treatment of various neurological and psychological conditions

·      Specific Applications

Certain conditions demonstrate particularly strong responses to neurofeedback compared to medication (Micoulaud-Franchi et al., 2015):

o   Anxiety Disorders – While anti-anxiety medications often require ongoing administration and can create dependency, neurofeedback training has shown lasting anxiety reduction in most cases after completion of treatment. Research indicates that neurofeedback specifically targeting alpha brainwave activity helps individuals develop internal self-regulation strategies that reduce anxiety levels without external chemical intervention.

o   Learning Disabilities – Neurofeedback’s ability to enhance cognitive processing and attention span produces sustainable improvements in academic performance, whereas medication effects typically remain dependent on continued use. Studies of children with specific learning disabilities show not only improved test scores but also enhanced learning capacity that persists beyond the training period.

This sustainability likely reflects neurofeedback's direct impact on neural networks involved in information processing and attention, creating lasting changes in how the brain processes and organizes learning experiences.

o   Sleep Disorders – Unlike sleep medications, which often lose effectiveness over time, neurofeedback-induced improvements in sleep patterns show remarkable stability. Research indicates the majority of patients maintain better sleep quality years after treatment completion.

By normalizing brainwave patterns associated with sleep onset and maintenance, neurofeedback helps establish healthy sleep cycles that continue to function properly without ongoing intervention.

Summary: Certain conditions demonstrate particularly strong responses to neurofeedback compared to medication (Micoulaud-Franchi et al., 2015)

·      Considerations for Treatment Selection (Neurofeedback vs Medication)

Despite neurofeedback's advantages, several factors influence treatment selection in clinical practice:

o   Initial response time – Medication’s rapid effects may be preferable in crises requiring immediate symptom management.

o   Insurance coverage – Medication approaches often receive better insurance coverage, though this gap is narrowing as evidence for neurofeedback accumulates.

o   Access to trained providers –Neurofeedback requires specialized equipment and training, potentially limiting availability in some geographic areas.

o   Individual responsiveness – Some individuals show stronger responses to one approach than the other, suggesting the value of personalized treatment selection.

In many cases, a combined approach may prove optimal, with medication providing initial symptom relief while neurofeedback builds long-term self-regulation skills. This integration allows for medication reduction over time as neurofeedback effects strengthen, minimizing potential side effects while maximizing sustainable benefits.

Conclusion

While both neurofeedback and medication-based treatments demonstrate effectiveness during active intervention, neurofeedback shows superior long-term outcomes across multiple conditions. Its ability to create sustainable changes through learning rather than chemical dependence represents a significant advantage in treatment approaches.

The non-invasive nature of neurofeedback, combined with its minimal side effect profile and comprehensive impact, makes it an attractive option for individuals seeking lasting improvements without ongoing medication use. As research continues to validate its effectiveness, neurofeedback is increasingly recognized as a valuable first-line treatment option, particularly in cases where long-term solutions are desired.

However, optimal treatment plans should consider individual factors including symptom severity, response history, and treatment goals. In some cases, a combined approach may maximize benefits by leveraging medication's rapid effects alongside neurofeedback's sustainable impact. The growing evidence base supporting neurofeedback's efficacy and sustainability suggests it deserves serious consideration within the broader landscape of neurological and psychological interventions.

This article was written by our trainer Marta Molina Asensi

-----

References

Arns, M., Clark, C. R., Trullinger, M., deBeus, R., Mack, M., & Aniftos, M. (2020). Neurofeedback and Attention-Deficit/Hyperactivity-Disorder (ADHD) in Children: Rating the Evidence and Proposed Guidelines. Appl Psychophysiol Biofeedback, 45(2), 39-48. https://doi.org/10.1007/s10484-020-09455-2

Choobforoushzadeh, A., Neshat-Doost, H. T., Molavi, H., & Abedi, M. R. (2015). Effect of neurofeedback training on depression and fatigue in patients with multiple sclerosis. Appl Psychophysiol Biofeedback, 40(1), 1-8. https://doi.org/10.1007/s10484-014-9267-4

Liao, Y.-C., Guo, N.-W., Su, B.-Y., Chen, S.-J., & Tsai, H.-F. (2022). Effects of Twenty Hours of Neurofeedback-Based Neuropsychotherapy on the Executive Functions and Achievements among ADHD Children. Clinical EEG and Neuroscience, 53(5), 387-398. https://doi.org/10.1177/15500594221101693

Lin, F. L., Sun, C. K., Cheng, Y. S., Wang, M. Y., Chung, W., Tzang, R. F., Chiu, H. J., Cheng, Y. C., & Tu, K. Y. (2022). Additive effects of EEG neurofeedback on medications for ADHD: a systematic review and meta-analysis. Sci Rep, 12(1), 20401. https://doi.org/10.1038/s41598-022-23015-0

Luo, X., Guo, X., Zhao, Q., Zhu, Y., Chen, Y., Zhang, D., Jiang, H., Wang, Y., Johnstone, S., & Sun, L. (2023). A randomized controlled study of remote computerized cognitive, neurofeedback, and combined training in the treatment of children with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry, 32(8), 1475-1486. https://doi.org/10.1007/s00787-022-01956-1

Micoulaud-Franchi, J. A., McGonigal, A., Lopez, R., Daudet, C., Kotwas, I., & Bartolomei, F. (2015). Electroencephalographic neurofeedback: Level of evidence in mental and brain disorders and suggestions for good clinical practice. Neurophysiologie Clinique/Clinical Neurophysiology, 45(6), 423-433. https://doi.org/https://doi.org/10.1016/j.neucli.2015.10.077

Peeters, F., Oehlen, M., Ronner, J., van Os, J., & Lousberg, R. (2014). Neurofeedback As a Treatment for Major Depressive Disorder – A Pilot Study. PLOS ONE, 9(3), e91837. https://doi.org/10.1371/journal.pone.0091837

Quevedo, K., Yuan Teoh, J., Engstrom, M., Wedan, R., Santana-Gonzalez, C., Zewde, B., Porter, D., & Cohen Kadosh, K. (2020). Amygdala Circuitry During Neurofeedback Training and Symptoms' Change in Adolescents With Varying Depression. Front Behav Neurosci, 14, 110. https://doi.org/10.3389/fnbeh.2020.00110

Rahmani, M., Mahvelati, A., Farajinia, A. H., Shahyad, S., Khaksarian, M., Nooripour, R., & Hassanvandi, S. (2022). Comparison of Vitamin D, Neurofeedback, and Neurofeedback Combined with Vitamin D Supplementation in Children with Attention-Deficit/Hyperactivity Disorder. Arch Iran Med, 25(5), 285-393. https://doi.org/10.34172/aim.2022.47

Rajabi, S., Pakize, A., & Moradi, N. (2020). Effect of combined neurofeedback and game-based cognitive training on the treatment of ADHD: A randomized controlled study. Applied Neuropsychology: Child, 9(3), 193-205. https://doi.org/10.1080/21622965.2018.1556101

Sudnawa, K. K., Chirdkiatgumchai, V., Ruangdaraganon, N., Khongkhatithum, C., Udomsubpayakul, U., Jirayucharoensak, S., & Israsena, P. (2018). Effectiveness of neurofeedback versus medication for attention-deficit/hyperactivity disorder. Pediatrics International, 60(9), 828-834. https://doi.org/https://doi.org/10.1111/ped.13641

Van Doren, J., Arns, M., Heinrich, H., Vollebregt, M. A., Strehl, U., & S, K. L. (2019). Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis. Eur Child Adolesc Psychiatry, 28(3), 293-305. https://doi.org/10.1007/s00787-018-1121-4

Yu, S. H., Tseng, C. Y., & Lin, W. L. (2020). A Neurofeedback Protocol for Executive Function to Reduce Depression and Rumination: A Controlled Study. Clin Psychopharmacol Neurosci, 18(3), 375-385. https://doi.org/10.9758/cpn.2020.18.3.375

Zafarmand, M., Farahmand, Z., & Otared, N. (2022). A Systematic Literature Review and Meta-analysis on Effectiveness of Neurofeedback for Obsessive-Compulsive Disorder. Neurocase, 28(1), 29-36. https://doi.org/10.1080/13554794.2021.2019790